Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. 2003

Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
Department of Neurosciences, University of California San Diego, 9500 Gilman Drive, Mail Code 0804, La Jolla, CA 92093-0804, USA.

BACKGROUND Hypersecretion of corticotropin releasing factor (CRF) has been implicated in both severe anxiety disorders and major depression. Although the role of the CRF1 receptor in the anxiogenic effects of CRF is well supported, the role of CRF2 receptors in anxiety-like behaviors is less clear. In rats, CRF increases the acoustic startle reflex (ASR) via its action in the extended amygdala, providing a putative measure of CRF-mediated anxiogenic activity. OBJECTIVE To characterize the effect of CRF on ASR in mice and determine the respective roles of CRF1 and CRF2 receptors in CRF-potentiated ASR. METHODS The present study examined: (1) the time course and dose response functions for the effects of human/rat (h/r)-CRF (0.02-0.6 nmol, ICV (intracerebroventricular)) on ASR in two inbred strains of mice; (2) the effects of the CRF1 receptor antagonist NBI-30775 (20 mg/kg, intraperitoneal) and the CRF2 receptor antagonist Antisauvagine-30 (1-10 nmol, ICV) on CRF-potentiated ASR and (3) the effects of the CRF2 receptor agonist urocortin 2 (0.2-6 nmol, ICV) on ASR in mice. RESULTS h/r-CRF significantly increased ASR in mice in a time-dependent manner with maximal efficacy at the 0.2 and 0.6 nmol doses. 129S6/SvEvTac mice exhibited a slightly increased duration of action and lower minimal effective dose threshold for CRF effects on ASR compared to C57BL/6J mice. Both selective CRF1)and CRF2)antagonists attenuated h/r-CRF-potentiated ASR without affecting acoustic startle when given alone. The selective CRF2 receptor agonist urocortin 2 increased ASR (1 and 2 nmol), albeit with less efficacy than the non-selective CRF receptor agonist h/r-CRF. CONCLUSIONS Both CRF1 and CRF2 receptors appear to contribute to the h/r-CRF-induced increases in ASR in mice. These data support the hypothesis that both receptors contribute to the anxiogenic effects of CRF.

UI MeSH Term Description Entries
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors

Related Publications

Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
September 2013, The international journal of neuropsychopharmacology,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
November 2021, Genes, brain, and behavior,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
June 2000, The Journal of pharmacology and experimental therapeutics,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
December 1994, Brain research,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
October 2003, Neuropharmacology,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
December 2012, Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
January 2002, Receptors & channels,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
December 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
January 2000, Polish journal of pharmacology,
Victoria B Risbrough, and Richard L Hauger, and Mary Ann Pelleymounter, and Mark A Geyer
September 1968, Nihon Ishikai zasshi. Journal of the Japan Medical Association,
Copied contents to your clipboard!